


Supplementary information, Fig. S9



Supplementary information, Fig. S9. EGFR phosphorylates RAB31 to drive EGFR into exosomes and the exosomes promoted by RAB31 mediate resistance to erlotinib. **a** Western blotting analyses of whole-cell lysates (WCL) from the indicated stable NCI-H1975 cells under serum starvation (SS). **b** Western blotting analyses of WCL from the indicated stable HeLa cells under SS. **c** Western blotting analyses of WCL and immunoprecipitates (IP) from the indicated stable NCI-H1975 cells treated with DMSO, afatinib or erlotinib under SS. **d** Immunofluorescence of endogenous EGFR (green) and CD63 (red) in NCI-H1975 cells treated with afatinib or erlotinib under SS. **e** Immunofluorescence of endogenous RAB31 (green) and CD63 (red) in NCI-H1975 cells treated with afatinib or erlotinib under SS. **f** Western blotting analyses of WCL from the indicated stable NCI-H1975 cells under SS. **g** Western blotting analyses of WCL and IP from the indicated stable NCI-H1975 cells under SS. **h** Western blotting analyses of the concentrated conditional media from the indicated stable NCI-H1975 cells used in **g**. **i** Representative clone images of PC9-GFP cells co-cultured with the indicated stable NCI-H1975 cells without or with erlotinib. **j**, Quantification of the cell numbers of 20 clones in each group in **i**. Data are means \pm S.D. of cell numbers of 20 clones in each group. Unpaired *t*-test was used to analyze the difference between the two groups. *****P* < 0.0001, NS, no statistical significance. **k** Density gradient fractionation of small EVs isolated from the concentrated conditional media derived from stable NCI-H1975 cells under SS. After flotation of sample in high-resolution iodixanol gradients, equal volumes of each fraction were loaded on SDS-PAGE gels, and membranes were blotted with the indicated antibodies. NV, non-vesicular; sEV, small EV. Scale bars, 10 μ m (**d** and **e**), 200 μ m (**i**).